- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05516719
Longitudinal Investigation of I2BS in PD (FOX_2)
Longitudinal Investigation of Imidazoline-2 Binding Site as a Novel Marker of Disease Progression in Parkinson's Disease: An [11C]BU99008 PET Study
Study Overview
Status
Conditions
Detailed Description
Parkinson's disease is a chronic neurological disease that progresses over time and causes a variety of symptoms, such as slowness of movement, stiffness and shaking. The purpose of this study is to find a biomarker for Parkinson's disease. A biomarker is an indicator of the presence of a disease, that can be measured, and that is able to give information.
The study will take place in London, in three research sites that are located near to each other. The NIHR Imperial Clinical Research Facility (CRF) at Hammersmith Hospital in London, for clinical assessment, and Invicro London for imaging assessments. Both Hammersmith Hospital and Invicro are located at Hammersmith Hospital Campus.
Taking part in this study will involve two sets of visits spaced out 12 months apart. These visits would include, initial screening and consent visit. The second visit would be for an MRI and PET scan with the tracer BU99008 which highlights astroglia cells. The third visit would be for a SPECT scan, and an optional fourth visit for a Lumbar Puncture procedure to collect spinal fluid for analysis.
These visits are then repeated 12 months later to form a comparison. The maximum number of visits for this study would be 8, however two of these visits are optional lumbar puncture visits.
The findings form this research will provide a deeper understanding of the brain changes in Parkinson's disease. More importantly, this study will help with the discovery and development of new medications aiming to delay progression of Parkinson's disease symptoms. n about the progression, or severity, of it.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Marios Politis, Professor
- Phone Number: 07503741242
- Email: M.Politis@exeter.ac.uk
Study Contact Backup
- Name: Edoardo De Natale, Dr
- Phone Number: 07503741242
- Email: e.de-natale@exeter.ac.uk
Study Locations
-
-
Devon
-
Exeter, Devon, United Kingdom, EX1 2LU
- Recruiting
- University of Exeter
-
Contact:
- Marios Politis, Professor
- Phone Number: 07503 741242
- Email: m.politis@exeter.ac.uk
-
Contact:
- Edoardo de Natale, Dr
- Phone Number: 07503 741242
- Email: e.de-natale@exeter.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion criteria
- All subjects must be judged by the investigator able to understand the nature, design, and procedures of the study and must be able to provide a signed and dated informed consent in accordance with Good Clinical Practice (GCP), International Conference on Harmonization (ICH), and local regulations.
- All subjects must be willing and able to comply with scheduled visits, required study procedures and laboratory tests.
- All subjects must be able to travel to the research sites for the study procedures.
- Age 25 years or older.
- For female subjects: They must be either of non-childbearing potential (either surgically sterile or post- menopausal - defined as 12 months of spontaneous amenorrhea), or, if of childbearing potential, subjects must demonstrate to be non-pregnant (as demonstrated by negative urine β-HCG test at screening), non-breastfeeding.
- All subjects must comply with highly effective contraceptive measures. A highly effective contraceptive measure is defined as a measure that can achieve a failure rate of less than 1% per year when used consistently and correctly. These methods are listed in more detail below:
Oral, intravaginal, or transdermal combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation;
Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation:
Intrauterine device (IUD)
Intrauterine hormone-releasing system (IUS)
Bilateral tubal occlusion
Vasectomised partner
Sexual abstinence
- For sexually active male subjects, they must agree to use condoms to protect their partners from becoming pregnant for the duration of the study and for 3 months after the last administration of PET or SPECT ligands. They must also agree to ensure that they and their partners are routinely using a medically approved contraceptive method. It is important that male subjects not impregnate others for the duration of the study and for 3 months after the last administration of PET or SPECT ligands.
- All subjects must have adequate visual and auditory acuity according to investigator's judgement to complete the psychological testing.
- All subjects must have no use of medications with known interaction with I2BS (e.g. idaxozan, efaroxan, yohimbine, atomoxetine, atipamezole, mianserin, mirtazapine, clonidine, guanfacine, guanabenz, guanethidine, xylazine, tizanidine, tedetomidine, methyldopa, fadolmidine, dexmedetomidine)
- For subjects taking any drugs that might interfere with dopamine transporter SPECT imaging (neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine, or amphetamine derivative) must be willing and able from a medical standpoint to hold the medication for at least 5 half-lives prior to screening DaTSCANä imaging.
Exclusion criteria
- Subjects lacking capacity according to investigator's judgment;
- Subjects with a clinical diagnosis of dementia as determined by the investigator;
- Subjects with current or a recent history of drug or alcohol abuse/dependence;
- Current treatment with anticoagulants (e.g. warfarin, heparin) that might preclude the arterial cannulation and the safe completion of the lumbar puncture.
- Condition that precludes the safe performance of routine lumbar puncture, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia.
- Negative Allen test in both hands,
- Use of any of the following drugs that might interfere with dopamine transporter SPECT imaging: neuroleptics, metoclopramide, alpha methyldopa, methylphenidate, reserpine, or amphetamine derivative, within 5 months of Screening.
- Use of any medications with known actions on I2BS (e.g. idaxozan, efaroxan, yohimbine, atomoxetine, atipamezole, mianserin, mirtazapine, clonidine, guanfacine, guanabenz, guanethidine, xylazine, tizanidine, tedetomidine, methyldopa, fadolmidine, dexmedetomidine);
- Use of investigational drugs or devices within 60 days prior to Baseline (dietary supplements taken outside of a clinical trial are not exclusionary, e.g., coenzyme Q10).
- History of cancer within the last 5 years, with the exception of non-metastatic basal cell carcinoma of the skin.
- Subjects with current or recent history of drug or alcohol abuse/dependence.
- Contraindication to MRI, such as presence of metal devises or implants (e.g. pacemaker, vascular- or heart- valves, stents, clips), metal deposited in the body (e.g. bullets or shells), or metal grains in the eyes;
- Claustrophobia or history of back pain that makes prolonged laying on the PET, SPECT, or MRI scanner intolerable.
- Previously obtained MRI scan with evidence of clinically significant neurological disorder (in the opinion of the Investigator).
- Presence of any clinically significant medical condition (including cardiovascular, respiratory, cerebrovascular, hematological, hepatic, renal, gastrointestinal, or other disease) that, based on the judgment of the investigator, is clinically unstable, is likely to deteriorate during the course of the study, could put the patient at risk because of participation in the study, could affect the subject's ability to complete the study, or could influence the study results;
- History of suicidal behavior or active suicidal ideation;
- Pregnancy or breastfeeding or intent to become pregnant in the next 18 months;
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
SNCA (Alpha-synuclein gene)
PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology
|
A positron emission tomography (PET) scan produce detailed 3-dimensional images of the inside of the body by showing radiation from tracers used to highlight specific areas of the brain.
A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain.
A lumbar puncture is where a thin needle is inserted between the bones in your lower spine using local anaesthetic.
This allows the collection of Cerebrospinal fluid ( CSF)
|
Idiopathic Parkinson's Disease
PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD pathology
|
A positron emission tomography (PET) scan produce detailed 3-dimensional images of the inside of the body by showing radiation from tracers used to highlight specific areas of the brain.
A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain.
A lumbar puncture is where a thin needle is inserted between the bones in your lower spine using local anaesthetic.
This allows the collection of Cerebrospinal fluid ( CSF)
|
Healthy Control
PET and SPECT molecular imaging and MRI; Clinical investigation and computerized neuropsychological testing; Collection of blood, urine and CSF biomarkers of PD patholog
|
A positron emission tomography (PET) scan produce detailed 3-dimensional images of the inside of the body by showing radiation from tracers used to highlight specific areas of the brain.
A single-photon emission computerized tomography (SPECT) scan allows analysis of brain function by creating 3D Pictures using compounds called tracers.
MRI (magnetic resonance imaging) uses magnets alongside radio waves to create pictures of the brain.
A lumbar puncture is where a thin needle is inserted between the bones in your lower spine using local anaesthetic.
This allows the collection of Cerebrospinal fluid ( CSF)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PET scan with BU99008 to highlight I2BS and and Astroglia cells.
Time Frame: 12 Months
|
This used to show the role of Astroglia cell activation in Parkinson's disease to understand the role of Astroglia in Parkinson's disease Pathophysiology
|
12 Months
|
Single Photon Emission Computed Tomography (SPECT) to measure brain molecular pathology
Time Frame: 12 Months
|
To quantify serotonergic pathology with BU99008 and dopaminergic pathology with Single-photon Emission Computed Tomography (SPECT)
|
12 Months
|
Magnetic Resonance Imaging (MRI)
Time Frame: 12 Months
|
Magnetic Resonance Imaging (MRI) to view structural and microstructural changes and structural connectivity..
|
12 Months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Time Frame: 12 Months
|
To determine if there is a correlation with neuropsychological and behavioural evaluation.
|
12 Months
|
Montreal Cognitive Assessment (MOCA) to determine if there is a correlation with neuropsychological and behavioural evaluation
Time Frame: 12 Months
|
A cognitive screening test designed to assist in the detection of mild cognitive impairment, scored out of 30
|
12 Months
|
Cambridge Neuropsychological Test Automated Battery (CANTAB) to determine if there is a correlation with neuropsychological and behavioural evaluation
Time Frame: 12 Months
|
Administered to detect cognitive issues & brain disorders efficiently.
|
12 Months
|
Symbol Digit Modalities Test (SDMT) to determine if there is a correlation with neuropsychological and behavioural evaluation
Time Frame: 12 Months
|
To be used in screening for organic cerebral dysfunction scored out of 110
|
12 Months
|
Beck Depression Inventory-II (BDI-II) to determine if there is a correlation with neuropsychological and behavioural evaluation
Time Frame: 12 Months
|
A brief, self-report inventory designed to measure the severity of depression symptomatology
|
12 Months
|
State-Trait Anxiety Inventory (STAI) to determine if there is a correlation with neuropsychological and behavioural evaluation
Time Frame: 12 Months
|
A commonly used measure of trait and state anxiety.
Used to diagnose anxiety and to distinguish it from depressive syndromes
|
12 Months
|
University of Pennsylvania Smell Identification Test (UPSIT) to determine if there is a correlation with neuropsychological and behavioural evaluation
Time Frame: 12 Months
|
This is used to test the function of an individual's olfactory system
|
12 Months
|
Movement Disorder Society- Non-Motor Symptoms scale for Parkinson's Disease MDS-NMSS to determine if there is a correlation with neuropsychological and behavioural evaluation
Time Frame: 12 Months
|
This is a 30-item rater-based scale to assess a wide range of non-motor symptoms in patients with Parkinson's disease
|
12 Months
|
Scales for Outcomes in Parkinson's Disease-Autonomic questionnaire - Autonomic Dysfunction (SCOPA-AUT) to determine if there is a correlation with neuropsychological and behavioural evaluation
Time Frame: 12 Months
|
A 25 item assessment to evaluate autonomic symptoms in patients with Parkinson's disease
|
12 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marios Politis, Professor, University of Exeter
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-21-15
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
-
BlueRock TherapeuticsMemorial Sloan Kettering Cancer CenterActive, not recruitingAdvanced Parkinson's DiseaseUnited States, Canada
Clinical Trials on Positron Emission Tomography (PET) scan using BU99008 tracer
-
University of ExeterRecruitingParkinson's Disease | Parkinson Disease | Neurodegenerative Diseases | Positron Emission Tomography | Neurodegeneration | Parkinson'sUnited Kingdom
-
The Methodist Hospital Research InstituteRecruitingHealthy | Alzheimer DiseaseUnited States
-
University of ExeterRecruitingParkinson Disease | Neurodegenerative Diseases | Neurodegenerative Disease, Hereditary | Parkinson's | Nervous System DisorderUnited Kingdom
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnOropharyngeal Squamous Cell Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma
-
University of Texas Southwestern Medical CenterWithdrawn
-
M.D. Anderson Cancer CenterGE HealthcareCompletedLung CancerUnited States
-
Centre Henri BecquerelCompleted
-
University of WashingtonNational Cancer Institute (NCI)CompletedAdult Solid NeoplasmUnited States
-
University of CincinnatiActive, not recruitingLiver Metastases | Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver CancerUnited States
-
Jagiellonian UniversityMedical University of WarsawCompletedNeurodegenerative Diseases | Brain Neoplasms | Neuroendocrine TumorsPoland